[Serous central chorioretinopathy and tadalafil: a case report]

S Nadeau; F Nguyen; S Guigou

doi:10.1016/j.jfo.2011.02.016

[Serous central chorioretinopathy and tadalafil: a case report]

J Fr Ophtalmol. 2012 Feb;35(2):121.e1-5. doi: 10.1016/j.jfo.2011.02.016. Epub 2011 Jun 15.

[Article in French]

Authors

S Nadeau¹, F Nguyen, S Guigou

Affiliation

¹ Centre hospitalier d'Avignon, hôpital Henri-Duffaut, 305, rue Raoul-Follereau, 84902 Avignon cedex 9, France. nadeausebastien@hotmail.fr

PMID: 21680058
DOI: 10.1016/j.jfo.2011.02.016

Abstract

We report a case of central serous chorioretinopathy in a 46-year-old man with no risk factors except for erectile dysfunction agent use: Tadalafil (Cialis(®)). An association between tadalafil and central serous chorioretinopathy could involve phosphodiesterase type 5 inhibitors and be a risk factor of central serous chorioretinopathy.

Publication types

Case Reports
English Abstract

MeSH terms

Carbolines / adverse effects*
Carbolines / therapeutic use
Central Serous Chorioretinopathy / chemically induced*
Central Serous Chorioretinopathy / diagnosis
Erectile Dysfunction / drug therapy
Humans
Male
Middle Aged
Phosphodiesterase 5 Inhibitors / adverse effects
Phosphodiesterase 5 Inhibitors / therapeutic use
Tadalafil
Vasodilator Agents / adverse effects
Vasodilator Agents / therapeutic use

Substances

Carbolines
Phosphodiesterase 5 Inhibitors
Vasodilator Agents
Tadalafil